3681.HK

SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company

Retrieved on: 
星期五, 十一月 4, 2022
Technology, Company, SM03, Pemphigus, Research, Central China, Therapy, Growth, Asthma, The Company, Non-Hodgkin lymphoma, State Council, NHL, Damage-associated molecular pattern, Lupus, Twelfth, Sino Biopharmaceutical Limited, SLE, Barakat Pharmaceutical Group, RA, Rheumatoid arthritis, The Group, Thirteenth, WANG, CD22, Autoimmune disease, B-cell lymphoma, Mab, Degenerative disease, Pharmaceutical industry, Group

Mr. Shanchun WANG, served as the executive director of Sino Biopharmaceutical Limited (stock code: 1177) and the president of Chia Tai - Tianqing Pharmaceutical Group Co. Ltd., joined SinoMab lately as the President (China) of the Company.

Key Points: 
  • Mr. Shanchun WANG, served as the executive director of Sino Biopharmaceutical Limited (stock code: 1177) and the president of Chia Tai - Tianqing Pharmaceutical Group Co. Ltd., joined SinoMab lately as the President (China) of the Company.
  • Mr. Shanchun WANG has rich experience and practical achievements in corporate strategic management, organizational management, innovation research and development and product commercialization.
  • Dr. Shui On LEUNG said that: "It is a great pleasure to have Mr. Shanchun WANG joining the Company.
  • Pursuant to the subscription agreement, Mr. Shanchun WANG conditionally agreed to subscribe for and the Company conditionally agreed to allot and issue 14,340,000 subscription shares.

Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA

Retrieved on: 
星期三, 八月 24, 2022
Ibrutinib, Investigational New Drug, The Company, Rheumatoid arthritis, Safety, CD22, Research, RA, Central nervous system, Degenerative disease, IND, Smoking, SLE, Mab, Disease, EBV, Multiple sclerosis, Epstein–Barr virus infection, R, National Medical Products Administration, Thirteenth, Asthma, B-cell lymphoma, Twelfth, NHL, NMPA, Antibody, Non-Hodgkin lymphoma, Neuromyelitis optica spectrum disorder, Company, Therapy, Lupus, PV, NMOSD, The Group, MS, Optic nerve, Optic neuritis, Spinal cord, Drug discovery, SM03, BTK, Trial of the century, Pemphigus, Pharmaceutical industry, Phase

The IND approval would enable the Company to initiate the Phase II/III clinical study in China to evaluate the efficacy and safety of SN1011 for the treatment of NMOSD in China.

Key Points: 
  • The IND approval would enable the Company to initiate the Phase II/III clinical study in China to evaluate the efficacy and safety of SN1011 for the treatment of NMOSD in China.
  • SN1011 differentiates from existing BTK inhibitors currently available in the market, such as Ibrutinib, in terms of mechanism of action, affinity, selectivity and safety.
  • Currently, four IND applications of SN1011 for the treatment of SLE, PV, MS and NMOSD have been approved by NMPA respectively.
  • SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases.